Abstract: An energy regeneration type forklift hydraulic system is provided, which includes a first oil pump, a first electrical motor, a multiple directional control valve, a lifting oil cylinder, a tilting oil cylinder, a steering oil cylinder, a load-sensing steering device, an oil filter, a second oil pump and an oil tank, wherein the multiple directional control valve includes an oil inletting and returning valve spool, a raising and lowering reversing valve spool, a tilting reversing valve spool, and an oil inletting valve spool. The raising and lowering reversing valve spool includes a raising and lowering three-position six-way reversing valve, an annular oil returning passage and an oil returning passage. The system can utilize the potential energy of lowering cargo to simultaneously drive two oil pumps for driving two motors to generate energy, thereby realizing energy recovery.

Abstract: The present invention provides a compound of Formula (1): as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication.

Abstract: The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: The present invention provides a compound of Formula (1): as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract: Dynamically selecting a DHCP server for a DHCP client terminal device, according to an example, includes: triggering, by a network device with a DHCP relay function, an authentication performed by an authentication server on a DHCP client terminal device user when receiving a DHCP packet for requesting a configuration parameter sent from a DHCP client terminal device; receiving, by the network device, an identity of a DHCP server designated by the authentication server for the DHCP client terminal device user when the DHCP client terminal device user passes the authentication, and establishing an entry for user information of the DHCP client terminal device user and the identity of the designated DHCP server; and matching, by the network device, the user information carried in a packet with established entries when receiving the packet subsequently sent from the DHCP client terminal device, and forwarding the packet using the identity of the DHCP server in the entry matching the user information.

Abstract: Silicone containing reactive monomers with hydrophilic end-groups of formula I useful in the manufacture of biocompatible medical devices are disclosed, wherein R1 is H or CH3, a is 0 or 1, p is an integer from 1 to 6, q is an integer from 1 to 3 and for each q, the end groups R51, R52, R53 are independently an alkyl, alkyl ether, trimethylsiloxy group, or a substituted or non-substituted aromatic group and at least one of them has a hydrophilic group attached, preferably to the terminal end of R51, R52, R53, X is O or NR54, where R54 is H or a monovalent alkyl group with 1 to 4 carbons, n is an integer from 1 to 100, R2 and R3 are independently an alkyl, alkyl ether, or a substituted or non-substituted aromatic group, preferred R2 and R3 include methyl, ethyl, and phenyl, L is a divalent linker comprising substituted and unsubstituted alkylene groups having 1-14 carbon atoms, which may be straight or branched, substituted and unsubstituted alkoxy groups having 2-12 carbons, polyethers, oxazolines, and substi

Abstract: The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis.

Abstract: A data communication method includes providing a sender node having a data packet of information. The data packet includes at least one first field and a second field. The second field has content that is dependent upon actual content of the at least one first field. The content of the second field of the data packet is transmitted from the sender node to a receiver node. The receiver node is used to predict the actual content of the first field of the data packet. The receiver node is used to calculate the content of the second field of the data packet based upon the predicted content of the first field. The predicted content of the first field is confirmed to be equivalent to the actual content of the first field. The confirming step includes comparing the calculated content of the second field to the transmitted content of the second field.

Abstract: The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract: A system includes a cooler configured to cool a first gas portion of a compressed gas fuel and discharge a cooled fluid. The cooled fluid comprises a cooled gas portion and a cooled liquid portion. The system also includes a separator configured to separate the cooled fluid into the cooled gas portion and the cooled liquid portion and a mixing tank configured to mix a second gas portion of the compressed gas fuel with the cooled gas portion in direct contact with one another to produce a superheated gas fuel. The superheated gas fuel comprises a degree of superheat above a lower threshold for a combustion system.

Abstract: Amphiphilic biomimetic phosphorylcholine-containing silicone compounds for use in both topical and internal applications as components in biomedical devices. The silicone compounds, which include zwitterionic phosphorylcholine groups, may be polymerizable or non-polymerizable. Specific examples of applications include use as active functional components in ophthalmic lenses, ophthalmic lens care solutions, liquid bandages, wound dressings, and lubricious and anti-thrombogenic coatings.

Abstract: Polymers having the formula R(LE)X wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and x endgroups, E is an endgroup that is covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain having at least 5 identical repeat units that is capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE)X in the polymer may be the same as or different from one another. Monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer, may be designed. Use of the polymer to fabricate a configured article from the surface-modified polymer or to fabricate a coating or topical treatment on an article made from another material.

Abstract: Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication.

Abstract: Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of ?-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of A? that are shown herein to be potent inhibitors of the activity of ?-secretase.

Abstract: Block copolymer having improved compression set comprising 40-98 wt-% soft segment, 1.9-20 wt-% hard segment, and 0.05-3 wt-% monofunctional ionic endgroups. The incorporation of ionomers into diisocyanate-based thermoplastic polyurethane materials greatly improves compression set with little impact on the overall TPU formulation. A typical formulation for making the block copolymer contains 84.2% polydimethylsiloxane, 12.9% diisocyanate, 2.9% diamine chain extender, 0.15% sodium 2-[bis(2-hydroxyethyl)amino]ethylsulfonate, and 0.05% isethionic acid. The polymeric material may be configured, for instance, as a contact lens, prosthetic spinal nucleus, orthopedic bearing surface, gasket, or sealant.

Abstract: An integrated system for interactive communication and multimedia support in a vehicle. The system includes a plurality of peripheral devices and a central control unit. Each of the peripheral devices is configured to be installed in the vehicle. The central control unit is also configured to be installed in the vehicle and has a communication interface. The communication interface includes first and second communication platforms and communicates with the plurality of peripheral devices via at least one of the first and second communication platforms. Each communication platform is configured to support bi-directional and selective communication between each of the peripheral devices.

Abstract: Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of ?-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of A? that are shown herein to be potent inhibitors of the activity of ?-secretase.